Eveliqure is a clinical-stage Austrian biotechnology company that has developed a proprietary vaccine
technology platform aiming at improving the quality of life for both the poor and the privileged by providing
innovative medical solutions to fight diarrhoeal diseases.
technology platform aiming at improving the quality of life for both the poor and the privileged by providing
innovative medical solutions to fight diarrhoeal diseases.
Shigella and ETEC are leading bacterial causes of diarrhoeal diseases worldwide, causing an estimated 200
million diarrhoea cases in children under five years of age. Infection with Shigella and ETEC can cause stunted growth among children, which has been linked to detrimental long-term health, developmental, and
economic outcomes. No effective vaccines against these two pathogens exist and previous attempts to
develop vaccines against Shigella and ETEC have failed.
million diarrhoea cases in children under five years of age. Infection with Shigella and ETEC can cause stunted growth among children, which has been linked to detrimental long-term health, developmental, and
economic outcomes. No effective vaccines against these two pathogens exist and previous attempts to
develop vaccines against Shigella and ETEC have failed.
This is a Phase 1b clinical trial for their ShigETEC vaccine candidate and this marks a significant milestone in Eveliqure’s mission to combat Shigellosis and ETEC diseases and contribute to global health.
Read the full press release here.
